CNS Pharmaceuticals Files S-1/A Amendment

TL;DR

<b>CNS Pharmaceuticals, Inc. has filed an S-1/A amendment, providing updated financial information and corporate details.</b>

AI Summary

CNS Pharmaceuticals, Inc. (CNSP) filed a Amended IPO Registration (S-1/A) with the SEC on January 10, 2024. CNS Pharmaceuticals, Inc. filed an S-1/A amendment on January 10, 2024. The filing relates to the Securities Act of 1933. The company's principal executive offices are located in Houston, Texas. The filing includes financial data for periods ending September 30, 2023, and December 31, 2022. The company is incorporated in Nevada and operates in the Pharmaceutical Preparations industry.

Why It Matters

For investors and stakeholders tracking CNS Pharmaceuticals, Inc., this filing contains several important signals. This amendment updates the company's registration statement, which is crucial for potential future stock offerings or significant corporate actions. The filing provides a snapshot of the company's financial position as of Q3 2023, offering insights into its performance and capital structure.

Risk Assessment

Risk Level: low — CNS Pharmaceuticals, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement (S-1/A), indicating ongoing regulatory processes rather than immediate financial distress or significant positive developments.

Analyst Insight

Monitor future filings for details on the company's strategic plans and financial performance following this amendment.

Key Numbers

• 2023-09-30 — Most Recent Financial Period End (Financial reporting period)
• 2022-12-31 — Prior Year End Financial Period (Financial reporting period)
• 2023-01-01 — Start of Current Reporting Period (Financial reporting period)
• 2022-01-01 — Start of Prior Year Reporting Period (Financial reporting period)

Key Players & Entities

• CNS Pharmaceuticals, Inc. (company) — Filer name
• 0001683168-24-000182 (filing_id) — Accession Number
• 2024-01-10 (date) — Filing Date
• 1933 Act (regulation) — SEC Act
• 333-275973 (filing_id) — SEC File Number
• Houston, TX (location) — Business Address
• NV (jurisdiction) — State of Incorporation
• 2834 (industry_code) — Standard Industrial Classification

FAQ

Industry Context

CNS Pharmaceuticals operates within the pharmaceutical preparations sector, focusing on the development of novel therapies.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities.

What Investors Should Do

1. Review the full S-1/A filing for detailed financial statements and disclosures.
2. Track future SEC filings from CNS Pharmaceuticals for updates on their business and financial condition.
3. Research the company's product pipeline and clinical trial progress.

Key Dates

• 2024-01-10: S-1/A Filing — Amendment to registration statement filed.

Year-Over-Year Comparison

This is an amendment to a previous filing, indicating updates and revisions to the company's registration statement.

Key Financial Figures

• $1.15 — sumed combined public offering price of $1.15 per share and accompanying common warra
• $0.001 — mmon stock and has an exercise price of $0.001 per share. The combined purchase price
• $1 — accompanying common warrant is equal to $1.149, which is equal to the combined pur
• $750,000 — eed to pay HPI: (i) development fees of $750,000 over a three-year period beginning Nove
• $50,000 — (ii) a 2% royalty on net sales; (iii) a $50,000 per year license fee; (iv) milestone pa
• $100,000 — license fee; (iv) milestone payments of $100,000 upon the commencement of a Phase II tri
• $1.0 million — he commencement of a Phase II trial and $1.0 million upon the approval of a New Drug Applica
• $1,134,000 — ancies. We agreed to fund approximately $1,134,000 over a two-year period. We paid and rec
• $334,000 — a two-year period. We paid and recorded $334,000 in 2020 related to this agreement in re
• $800,000 — statements of operations. The remaining $800,000 was paid in 2021. The principal investi
• $1.28 — hares of the Company's common stock, at $1.28 per share, in exchange for the Company'

Filing Documents

• cnspharma_s1a1.htm (S-1/A) — 1348KB
• cnspharma_ex2301.htm (EX-23.1) — 3KB
• 0001683168-24-000182.txt (&nbsp;) — 3686KB
• cnsp-20230930.xsd (EX-101.SCH) — 19KB
• cnsp-20230930_cal.xml (EX-101.CAL) — 25KB
• cnsp-20230930_def.xml (EX-101.DEF) — 106KB
• cnsp-20230930_lab.xml (EX-101.LAB) — 204KB
• cnsp-20230930_pre.xml (EX-101.PRE) — 172KB
• cnspharma_s1a1_htm.xml (XML) — 271KB

RISK FACTORS

RISK FACTORS 6 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 21

DILUTION

DILUTION 23 CAPITALIZATION 25

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 26

BUSINESS

BUSINESS 30 MANAGEMENT 46 EXECUTIVE AND DIRECTOR COMPENSATION 49 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 53

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 55

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 56 DESCRIPTION OF PRE-FUNDED WARRANTS 59 DESCRIPTION OF COMMON WARRANTS 60 PLAN OF DISTRIBUTION 61 LEGAL MATTERS 63 EXPERTS 63 WHERE YOU CAN FIND MORE INFORMATION 64 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the SEC to register the securities offered hereby under the Securities Act. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. You should carefully read this prospectus before deciding to invest in our securities. We have not, and the placement agents have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We have not, and the placement agents have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions r

View Full Filing

View this S-1/A filing on SEC EDGAR